Shilpa Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SHILPA, and when can generic versions of SHILPA drugs launch?
SHILPA has thirteen approved drugs.
There are five US patents protecting SHILPA drugs. There are two tentative approvals on SHILPA drugs.
There are fifty-four patent family members on SHILPA drugs in twenty-six countries and forty-eight supplementary protection certificates in sixteen countries.
Summary for Shilpa
International Patents: | 54 |
US Patents: | 5 |
Tradenames: | 11 |
Ingredients: | 11 |
NDAs: | 13 |
Patent Litigation for Shilpa: | See patent lawsuits for Shilpa |
Drugs and US Patents for Shilpa
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shilpa | ERLOTINIB HYDROCHLORIDE | erlotinib hydrochloride | TABLET;ORAL | 211960-002 | Nov 5, 2019 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Shilpa | DOCETAXEL | docetaxel | INJECTABLE;INJECTION | 205934-001 | Dec 22, 2015 | AP | RX | Yes | Yes | 9,763,880 | ⤷ Try a Trial | ⤷ Try a Trial | |||
Shilpa | APREMILAST | apremilast | TABLET;ORAL | 211774-003 | Apr 7, 2023 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Shilpa Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
South Korea | 102165394 | ⤷ Try a Trial |
Israel | 237930 | ⤷ Try a Trial |
Brazil | 112012028037 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Shilpa Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0817775 | 5/2006 | Austria | ⤷ Try a Trial | PRODUCT NAME: ERLOTINIB UND SEINE PHARMAZEUTISCH ANNEHMBAREN SALZE, INSBESONDERE ERLOTINIBHYDROCHLORID; NAT. REGISTRATION NO/DATE: EU/1/05/311/001 - EU/1/05/311/003 20050919; FIRST REGISTRATION: CH 57266 01 - 57266 03 20050321 |
0258618 | SPC/GB01/042 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: ZOLEDRONIC ACID 2-(IMIDAZOL-1-YL)-1-HYDROXYETHANE-1,1-DIPHOSPHONIC ACID; REGISTERED: CH 55463 20001128; UK EU/1/01/176/001 20010320; UK EU/1/01/176/002 20010320; UK EU/1/01/176/003 20010320 |
0564409 | 2002/005 | Ireland | ⤷ Try a Trial | PRODUCT NAME: IMATINIB OR ONE OF ITS PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS, ESPECIALLY THE MONOMETHANESULFONATE SALT; NAT REGISTRATION NO/DATE: EU/1/01/198/001-006 20011107; FIRST REGISTRATION NO/DATE: CH 55807 55807 01 55807 02 20010621; PAEDIATRIC INVESTIGATION PLAN: P/0028/2012 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.